TABLE 4.
Experimental and clinical trials with drug targeting histone methylation modulators in BCa cancer.
| Target | Drug | Combination | Tumor type | Status | Trial number | References |
|---|---|---|---|---|---|---|
| PRMT5 | GSK3326595 | Pembrolizumab | Metastatic transitional cell carcinoma of the urinary system (mTCC) | active | NCT02783300 | GlaxoSmithKline (2016) |
| PF-06939999 | - | Bladder carcinoma | active | NCT03854227 | Pfizer (2019) | |
| EZH2 | Tazemetostat | Pembrolizumab | Stage III-IV BCa Metastatic Urothelial Carcinoma | active | NCT03854474 | National Cancer Institute (2019) |
| CPI-0209 | - | Urothelial carcinoma (solid tumors) | active | NCT04104776 | U.S. National Library of Medicine (2019) | |
| G9a | BIX-01294 | - | Urothelial carcinoma | Not in clinical trial | - | Cui et al. (2015) |
| CM-272 | - | Urothelial carcinoma | Not in clinical trial | - | Zhu et al. (2019) |